AEZS vs. KERX
Gruß vom
Advamillionär
Kürzere Zockerphasen wird es sicherlich hier noch ein paar geben, aber mehr wohl kaum. Dazu taugt das "Gesamtkonstrukt" hier einfach nicht (mehr).
Gruß vom
Advamillionär
Front. Chem., 07 July 2020
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
https://www.frontiersin.org/articles/10.3389/fchem.2020.00571/full
The GnRH receptor is expressed in many endocrine cancers, including breast, ovarian, endometrial, and prostate tumors. Its presence provides the means to target oncolytic drugs to these cancer cells to supplement the clinical benefits currently achieved with ADT alone [90,95]. Zoptarelin Doxorubicin (AN-152, AEZS-108, ZoptrexTM) is a peptide-drug conjugate composed of a GnRH analog and doxorubicin through an ester bond with a glutaric acid spacer (Figure 2) [96]. The conjugate proved more effective than doxorubicin in inhibiting cell proliferation in GnRH receptor positive cancer cell lines [96]. It also was more potent than either agent alone in several xenograft mouse tumor models [97]. These results validate the virtue of targeted, complementary GnRH and doxorubicin pharmacology. Phase 1 studies in endometrial, ovarian and prostate cancer established Zoptarelin Doxorubicin’s safety, pharmacokinetics, and maximum tolerated dose [98,99,100]. In several phase 2 studies the drug-conjugate exhibited promising clinical activity with low systemic toxicity in castration and taxane-resistant prostate cancer [101], advanced or recurrent endometrial cancer [102], and platinum refractory ovarian cancer [103]. In a recent large phase 3 registration trial in advanced endometrial cancer Zoptarelin Doxorubicin disappointedly failed to improve median overall survival, or progression-free survival when compared to standard doxorubicin therapy [104]. The basis of the failure is unknown but given that doxorubicin at highest dose did not significantly improve patient survival there is a suspicion that deficiencies specific to doxorubicin might be the primary cause, as opposed to something inherent to the drug-conjugate.
....... the bid price for the Company’s common stock had closed below $1.00 per share for the prior 30 consecutive business day period, and that the Company has been provided a grace period of 180 calendar days.......
Gestern waren die 30 Tage um.
Sollte das wider Erwarten nicht der Fall sein, dann können wir uns im Spätherbst damit beschäftigen, aber nicht schon jetzt.
Gruß vom
Advamillionär
Selbst ein RS ist dann noch möglich. Das Listing ist eigentlich sicher seit der KE.
Some of the key players operating in the market are Novo Nordisk A/S; Pfizer, Inc.; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc. (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; and Ipsen. Several companies focus on developing long-acting human growth hormones.
The major companies operating in the market are adopting mergers, partnerships, and acquisitions as key strategies to expand their geographic reach and provide access to their solutions. For instance, in October 2018, Novo Nordisk and Strongbridge Biopharma signed an agreement to acquire the rights to MACRILEN in U.S. and Canada. MACRILEN (macimorelin) is the first and only oral drug approved by the FDA for use in adult growth hormone deficiency diagnosis.
https://www.grandviewresearch.com/...uman-growth-hormone-drugs-market
Die bekommen ja was vom Kuchen ab.
Die Bindefrist kann ich nicht finden.